Investigational Drug Shows Potentialin Phase 3 Obesity Trial - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Investigational Drug Shows Potentialin Phase 3 Obesity Trial

In a 76-week randomized trial, patients with obesity without diabetes who received survodutide achieved greater weight loss and favorable changes in several metabolic measures compared with those who received placebo.

  • By

  • Andrea Surnit

  • June 10, 2026

  • 4 min

Share

  • 1

    Survodutide significantly reduced body weight in patients with obesity over 76 weeks compared to placebo in the phase 3 SYNCHRONIZE-1 trial.

  • 2

    Patients receiving survodutide 3.6 mg and 6.0 mg achieved mean weight losses of approximately 12% and 13%, respectively, versus over 5% for placebo.

  • 3

    Higher percentages of patients on survodutide achieved substantial weight loss thresholds: 55% and 57% lost at least 10%, compared to 26% on placebo.

  • 4

    Survodutide also led to greater reductions in waist circumference and improvements in metabolic markers compared to placebo.

  • 5

    Adverse gastrointestinal events were more common in survodutide groups, with discontinuation rates due to these events at 18% and 20%.

Original Source(s)

Investigational Drug Shows Potentialin Phase 3 Obesity Trial

  • by Andrea Surnit

  • June 10, 2026

Related Content

Estriol may ease menopause-related cognitive decline

Women reported improvement across 6 cognitive domains during 12 months of estriol-based treatment, while murine models suggested a potential astrocyte-mediated mechanism.

10 states that support physician work-life balance

These 10 states have paid family or medical leave programs and health, wellness, peer support, or monitoring resources available to physicians or other health professionals.

TOFA may drive weight loss without reducing food intake

The oral compound increased energy expenditure, reduced fat mass, and improved metabolic measures in male mouse models.